Journal of Alzheimer's disease reports最新文献

{"title":"Latinos' beliefs about Alzheimer's disease symptoms: Their nature, variability, predictability, and severity.","authors":"María Cabán, Courtney Brown-Bradley, John B Wetmore, Ruth Ottman, Karolynn Siegel","doi":"10.1177/25424823261486002","DOIUrl":"10.1177/25424823261486002","url":null,"abstract":"<p><strong>Background: </strong>Latinos will experience the largest increase in Alzheimer's disease (AD) prevalence over the coming decades. Yet little is known about their beliefs regarding AD symptoms and their variability, predictability, and severity.</p><p><strong>Objective: </strong>To examine Latinos' beliefs regarding the symptoms associated with AD, their variability and predictability and whether their severity differs across individuals.</p><p><strong>Methods: </strong>A sample of 159 Latinos aged 40-64 living in Northern Manhattan completed baseline interview questions about AD symptoms and their variability and predictability. Data were coded using ATLAS.ti and content analyzed.</p><p><strong>Results: </strong>Cognitive symptoms such as forgetfulness and memory loss, disorientation, confusion and inability to recognize familiar people, were most frequently reported as AD symptoms. Behavioral and emotional symptoms were less frequently mentioned. Most believed symptoms, and their severity, varied across individuals and at least some aspects of symptoms were believed to be unpredictable. Factors believed to be associated with variability in symptoms and severity included lifestyle, reaction to diagnosis, overall health status, life experiences, family support, medical care, social and physical environment, and individual differences including genetics.</p><p><strong>Conclusions: </strong>Most participants recognized the core cognitive symptoms of AD but not the wider variety of symptoms those with the disease may experience. They offered numerous factors that might account for why symptoms and their severity differ across individuals. Educational interventions should emphasize the array of symptoms and their potential variability in occurrence and severity as well as their unpredictability in order to assist Latino families with identifying and managing AD in loved ones.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261486002"},"PeriodicalIF":2.8,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multivariate plasma pathology-cognition axis reveals biologically anchored residual cognitive heterogeneity across the Alzheimer's disease clinical spectrum.","authors":"Wei Han, Shaoyuan Lei, Na Li, Peishen Wang, Wenhao An, Xinye Han, Yihua An","doi":"10.1177/25424823261492239","DOIUrl":"10.1177/25424823261492239","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) pathology does not fully determine clinical expression, as individuals with similar biomarker-defined burden may show substantial differences in cognition. Characterizing cognitive variation beyond pathological burden may improve understanding of clinical heterogeneity in AD.</p><p><strong>Objective: </strong>To develop a multivariate plasma pathology-cognition framework that derives a pathology-anchored residual phenotype capturing cognitive variation beyond circulating pathological burden and to evaluate its clinical and longitudinal relevance.</p><p><strong>Methods: </strong>We analyzed 868 participants from the Alzheimer's Disease Neuroimaging Initiative with plasma p-tau217, glial fibrillary acidic protein, and neurofilament light chain measurements, cognitive assessments, and clinical characterization. Canonical correlation analysis derived a multivariate plasma pathology index and cognitive composite based on memory and language performance. The residual phenotype was defined as the deviation between observed cognition and cognition expected from plasma pathology burden. Clinical correlates and longitudinal trajectories were evaluated using regression and mixed-effects models. Biological validity was assessed by examining associations with amyloid-β and tau positron emission tomography measures.</p><p><strong>Results: </strong>The first canonical correlation between plasma markers and cognition was significant (r = 0.610, permutation p < 0.001). The plasma pathology index correlated with amyloid-β and tau positron emission tomography measures. The resulting pathology-anchored residual phenotype was associated with clinical diagnosis, education, <i>APOE</i> ε4 status, and sex. Higher residual scores reflected better-than-expected cognition relative to plasma pathology burden and were associated with slower subsequent decline in memory and language.</p><p><strong>Conclusions: </strong>A plasma pathology-anchored residual phenotype captures clinically meaningful cognitive heterogeneity beyond circulating biomarkers and provides a scalable framework for investigating differential clinical manifestations of AD pathology.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261492239"},"PeriodicalIF":2.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biobank Alzheimer Center Limburg study: A multimodal longitudinal dementia biobank.","authors":"Inez H G B Ramakers, Leonie C P Banning, Willemijn J Jansen, Lieke Bakker, Ron L H Handels, Sebastian Köhler, Pieter Jelle Visser, Stephanie J B Vos, Pauline Aalten, Frans R J Verhey","doi":"10.1177/25424823261496546","DOIUrl":"https://doi.org/10.1177/25424823261496546","url":null,"abstract":"<p><strong>Background: </strong>There is an urgent need to better understand the mechanisms of dementia, particularly Alzheimer's disease (AD), the most common subtype. The BioBank Alzheimer Center Limburg (BBACL) study is an ongoing prospective cohort, including consecutive patients from the memory clinic of the Alzheimer Center Limburg, Maastricht University Medical Center+, the Netherlands. It aims to investigate the natural course of cognitive complaints and identify early clinical and biological determinants of disease progression.</p><p><strong>Objective: </strong>To describe the BBACL study design and procedures and present the baseline characteristics of the currently included participants.</p><p><strong>Methods: </strong>Patients undergo standardized assessment, including demographics, comorbidities, cognitive and functional assessments, neuropsychiatric symptoms, MRI cerebrum, and biomaterials [blood and cerebrospinal fluid (CSF) samples (subset)]. Additional blood and CSF samples are stored for future biomarkers research. Follow-up is scheduled at 1, 2, 5, and 10 years.</p><p><strong>Results: </strong>Since its start in 2009, 920 patients have been included at baseline. The mean baseline age was 68.4 (SD 11.3) years, with 41.6% being females. The mean Mini-Mental State Examination score was 27.0 (SD 2.6). At baseline, 39.6% had subjective cognitive decline, 40.0% mild cognitive impairment, and 20.4% dementia (58.0% probable/possible AD and 19.7% mixed AD/vascular dementia), reflecting the study's emphasis on early diagnostics. Cognitive, functional, and biomarker measures varied across diagnostic groups as expected.</p><p><strong>Conclusions: </strong>BBACL combines extensive biospecimens with rich multimodal phenotyping and longitudinal follow-up, creating opportunities for future integrative analyses and omics-based analyses to uncover novel biological signatures.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261496546"},"PeriodicalIF":2.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How can physicians empathetically deliver a diagnosis that reflects the evolving landscape of Alzheimer's disease care: A scoping review.","authors":"Asha Duhan, Wei-Hsin Lu, Stephen Post","doi":"10.1177/25424823261476636","DOIUrl":"10.1177/25424823261476636","url":null,"abstract":"<p><p>Communicating an Alzheimer's disease (AD) diagnosis requires physicians to navigate not only complex symptoms but also profound psychosocial challenges influencing family dynamics and long-term neuropsychiatric care planning. The research landscape of AD has undergone a rapid transformation, marked by disease-modifying therapies such as lecanemab and donanemab. This study examines physician practices in AD diagnostic disclosure, clinician training for these conversations, and adaptations to emerging disease-modifying therapies. A structured scoping review was conducted using PubMed, PsycINFO, and Web of Science. The review focused on three themes: (1) best practices in diagnostic disclosure, (2) barriers to effective communication, and (3) physician training. A survey of neurologists and psychiatrists at the Renaissance School of Medicine is underway to assess their perspectives on discussing disease-modifying therapies with patients. The database search identified 337 records; after duplicates were removed, 245 were screened, 66 full texts assessed, and 23 studies included. Physicians emphasized the importance of helping patients maintain a sense of control, offering practical advice, and connecting patients to health and social intervention services. Physicians reported low confidence in conveying uncertainty, describing tension between honesty about limitations and preserving hope. With few formal opportunities, physicians rely on peers or supplemental resources to refine communication strategies. The scoping review found few studies on novel therapies' impact on diagnostic conversations and no formal guiding frameworks. This gap highlights the need to investigate physicians' approaches to discussing disease-modifying therapies for AD, which forms the basis of ongoing research.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261476636"},"PeriodicalIF":2.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CORRIGENDUM to \"For patients living in the \"Dementia Gap\", a newly defined substage of late-stage Alzheimer's disease, with intolerable suffering: Can sedation to unconsciousness be moral? \".","authors":"","doi":"10.1177/25424823261490482","DOIUrl":"https://doi.org/10.1177/25424823261490482","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/25424823261460085.].</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261490482"},"PeriodicalIF":2.8,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher thyroid-stimulating hormone level may delay dementia progression in patients without thyroid dysfunction.","authors":"Chien-Yu Su, Yi-Sin Wong, Chun Lee, Sheng-Feng Sung, Chi-Shun Wu, Yu-Hsiang Su, Mao-Hsun Lin, Cheung-Ter Ong","doi":"10.1177/25424823261494184","DOIUrl":"https://doi.org/10.1177/25424823261494184","url":null,"abstract":"<p><strong>Background: </strong>Although thyroid dysfunction causes reversible cognitive impairment, the role of thyroid-stimulating hormone (TSH) variation within the normal range in dementia progression remains unclear.</p><p><strong>Objective: </strong>To evaluate the association between baseline euthyroid TSH levels and cognitive decline rate in dementia patients.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using Taiwan's Ditmanson Research Database (2015-2022). Dementia patients with normal thyroid function who initiated anti-dementia medication were included; those with overt thyroid disease, malignancy, or CNS infections were excluded. Baseline TSH (within 180 days prior to treatment) was stratified by the cohort median (1.392 μIU/mL) into Low and High TSH groups. Longitudinal cognitive outcomes were tracked via repeated Mini-Mental State Examination (MMSE) scores over 3 years. Generalized estimating equation (GEE) models evaluated the TSH-cognitive decline association, adjusting for age, sex, baseline MMSE, medication class, and vascular comorbidities.</p><p><strong>Results: </strong>A total of 402 patients (955 MMSE observations) were analyzed. Baseline characteristics were comparable between groups. In adjusted analyses, the Low TSH group declined by 1.44 MMSE points per year (95% CI: -1.90 to -0.97; p < 0.001). A significant time-by-TSH group interaction (beta = 0.76, 95% CI: 0.17 to 1.34; p = 0.011) indicated a slower annual decline in the High TSH group (-0.68 points/year).</p><p><strong>Conclusions: </strong>Among euthyroid dementia patients, higher baseline TSH levels within the reference range were associated with significantly slower cognitive decline. These findings suggest physiological TSH variations may influence neurodegenerative progression, warranting further prospective research to clarify causality.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261494184"},"PeriodicalIF":2.8,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of digital multidomain cognitive testing in mild cognitive impairment and dementia assessment in primary care.","authors":"Wobbie Van den Hurk, Maria M Johansson, Elisabet Classon, Anders Gustavsson, Katarina Nägga, Anna Segernäs","doi":"10.1177/25424823261492238","DOIUrl":"https://doi.org/10.1177/25424823261492238","url":null,"abstract":"<p><strong>Background: </strong>Primary care plays a central role in identifying and monitoring mild cognitive impairment (MCI), Alzheimer's disease and other dementias, yet access to suitable cognitive assessment tools remains limited.</p><p><strong>Objective: </strong>To evaluate the feasibility, acceptability, usability and preliminary clinical validity of a digital multidomain cognitive test battery in routine primary care neurocognitive assessments.</p><p><strong>Methods: </strong>A total of 77 patients undergoing neurocognitive assessment across eight Swedish primary care centers were recruited and grouped by final diagnosis: 26 subjective cognitive impairment (SCI), 28 MCI, and 23 dementia. Participants completed a digital cognitive test battery consisting of eight traditional tests administered on the Mindmore platform via touchscreen tablets and supervised by occupational therapists (OTs). Clinicians were blinded to test results. Cognitive performance was compared across diagnostic groups and against normative data. Patient and OT experiences were collected using structured surveys.</p><p><strong>Results: </strong>Cognitive performance declined progressively from SCI to MCI to dementia on all tests. The battery yielded a detailed cognitive profile spanning 10 main test results across five cognitive domains. All included patients completed the test battery, they reported clear instructions, and 58% preferred tablet-based over paper-based testing. OTs considered the battery appropriately challenging in this population, provided some assistance in 69% of cases, and expected the battery to yield reliable results.</p><p><strong>Conclusions: </strong>These findings support the feasibility of integrating multidomain digital cognitive testing in primary health care with limited clinician burden. This is a promising approach for increasing availability of standardized detailed cognitive assessments at early levels of care.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261492238"},"PeriodicalIF":2.8,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uptake and safety profile of anti-amyloid immunotherapies in routine clinical practice.","authors":"Jay B Lusk, Kate Vinita Fitch, Kim G Johnson, Andy Liu, Jennifer L Lund, Laine E Thomas, Ryan McDevitt, Anqi Zhao, Heather E Whitson, Richard O'Brien, Shannon Aymes, Bradley G Hammill, Brian Mac Grory, Fan Li, Emily C O'Brien","doi":"10.1177/25424823261483526","DOIUrl":"10.1177/25424823261483526","url":null,"abstract":"<p><strong>Background: </strong>Anti-amyloid immunotherapies are approved by the United States Food and Drug Administration for the treatment of Alzheimer's disease; however, the adoption and safety profile of these medications in routine clinical practice have not been described.</p><p><strong>Objective: </strong>To describe the adoption and safety profile of anti-amyloid immunotherapies in routine clinical practice.</p><p><strong>Methods: </strong>This was a retrospective observational cohort study using target trial emulation methods. The data source was nationwide electronic health record data from Epic Cosmos. The primary exposure was the first prescription of anti-amyloid immunotherapy versus the active comparator of oral dementia therapy (acetylcholinesterase inhibitor (AChEI) or memantine, selected to minimize bias by baseline health status and disease severity). The primary end point was time to first nontraumatic intracranial hemorrhage (ICH). Propensity score overlap weighting was used to balance baseline demographic and clinical characteristics across treatment groups.</p><p><strong>Results: </strong>Between July 1, 2023 and January 1, 2025, 2616 patients (median age 74.8 years [IQR 69.8-78.8]; 53.9% female) were prescribed anti-amyloid immunotherapy (with or without AChEI/memantine), and 1,065,192 patients (median age 79.98 [IQR 73.6-85.6], 57.9% female) were prescribed AChEI/memantine alone. In total, 401 patients prescribed anti-amyloid immunotherapy and 274,470 patients prescribed AChEI/memantine were assessed for safety endpoints. Compared with AChEI/memantine, the analysis did not detect a statistically significant association between prescription of anti-amyloid immunotherapy and ICH (owHR 0.73 [95% CI 0.10-5.12]).</p><p><strong>Conclusions: </strong>The study did not detect a statistically significant association between prescription of anti-amyloid immunotherapy and ICH. The small treated cohort and low event count yielded imprecise estimates; these findings do not confirm safety and cannot exclude a clinically important increase in risk.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261483526"},"PeriodicalIF":2.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The trajectory of delusions in patients with Alzheimer's disease receiving pharmacological treatment: A re-analysis of data from the CATIE-AD trial.","authors":"Katsuharu Yano, Tomoyuki Nagata, Shinichiro Nakajima, Shinsuke Kito, Shunichiro Shinagawa","doi":"10.1177/25424823261494480","DOIUrl":"https://doi.org/10.1177/25424823261494480","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have reported decreases in the proportion of patients with delusions and severity of delusions during long-term follow-up in Alzheimer's disease (AD).</p><p><strong>Objective: </strong>The aim of the present study was to explore clinical predictors of the disappearance of delusions in AD patients enrolled in the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) trial who received pharmacological treatment.</p><p><strong>Methods: </strong>We re-analyzed the data of 421 clinic-based patients enrolled in the CATIE-AD trial to examine the association between the disappearance of delusions and relevant factors selected by reference to previous studies at week 12, 24, and 36 of treatment. Generalized Estimating Equations were used to analyze the impact of the assigned medication (mainly atypical antipsychotics), treatment duration, and their interaction on the disappearance of delusions over time.</p><p><strong>Results: </strong>The proportion of patients with delusions (PWD) gradually decreased to approximately 50% over the 36-week treatment period; however, no significant differences in the baseline variables were identified between the PWD and patients without delusions (POD) at any of the follow-up time-points (weeks 12, 24, or 36). Furthermore, the treatment duration was found to contribute significantly to the disappearance of delusions over time (conversion from PWD at baseline to POD at subsequent follow-up visits), independent of active drug use.</p><p><strong>Conclusions: </strong>Disappearance of delusions in AD patients was associated with the interval from the baseline, regardless of the use of active drugs. Insights into the natural course of delusions could guide clinicians toward selecting alternative treatment strategies for patients with AD.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261494480"},"PeriodicalIF":2.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dissecting the sex-dependent muscle-brain axis: Hippocampal subfields mediate the association between grip strength and cognition in amnestic mild cognitive impairment.","authors":"Wen-Juan Song, Guo-Hui Zhang, Pu Zhao, Jia-Jia Wu, Juan-Juan Lu, Jie Ma, Xu-Yun Hua, Jian-Guang Xu","doi":"10.1177/25424823261493009","DOIUrl":"https://doi.org/10.1177/25424823261493009","url":null,"abstract":"<p><strong>Background: </strong>Grip strength has been increasingly recognized as a potential indicator of cognitive decline and is closely associated with hippocampal structure. However, whether this muscle-brain relationship differs by sex among individuals with amnestic mild cognitive impairment (aMCI) remains unclear.</p><p><strong>Objective: </strong>To explore sex-specific relationships among grip strength, hippocampal subfield volumes and cognitive function in aMCI.</p><p><strong>Methods: </strong>This case-control study enrolled 144 aMCI patients and 84 healthy controls, demographic, neuropsychological, grip-strength data and 3.0 T MRI images were collected. Principal component analysis (PCA), multivariate regression, Pearson correlation and mediation analyses were performed.</p><p><strong>Results: </strong>Significant differences were found in the volumes of 15 hippocampal subfields, education level, right grip strength and cognitive scores. A bilateral grip strength related factor extracted by PCA was significantly associated with global cognition, memory, language, executive function and emotional status. Sex-stratified analyses revealed sex-specific correlations between grip strength, cognitive scores and hippocampal subfield volumes. Right hippocampal fissure partially mediated (20.33%) the relationship between right grip strength and ACE-III scores in males.</p><p><strong>Conclusions: </strong>Grip strength was correlated with hippocampal subfield integrity and cognitive function in a sex-specific manner. These observations illustrated an associative pathway linking muscular strength to cognitive vulnerability, with grip strength representing a potential observational marker for early-stage cognitive risk.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261493009"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}